type-2 inflammation
-
At the Border of Swallowing: One Antibody, Three Diseases, and a Trial That Landed
Tezepelumab met both co-primary endpoints in the Phase III CROSSING trial for eosinophilic esophagitis, holding gains to week 52 across 368 patients. The detail matters:…